Literature DB >> 26352988

Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.

Aisulu Usubalieva1, Christopher R Pierson, Christina A Kavran, Kristin Huntoon, Oleksandr N Kryvenko, Theodore G Mayer, Weiqiang Zhao, Jack Rock, Mario Ammirati, Vinay K Puduvalli, Norman L Lehman.   

Abstract

Primary meningeal gliomas are rare tumors composed of a heterogeneous group of neoplasms. We present 2 clinically aggressive cases of primary meningeal pleomorphic xanthoastrocytoma that clinically mimicked meningioma. One case presented in the posterior fossa of a 56-year-old woman; the other centered on the left operculum of a 35-year-old woman. These cases showed many of the classic features of pleomorphic xanthoastrocytoma, except that xanthomatous cells were rare and eosinophilic granular bodies were inconspicuous. Both cases exhibited high proliferative indices and superficially invaded the brain. One case harboring a BRAF mutation disseminated to the thecal sac and showed a clinical response to the targeted BRAF inhibitor dabrafenib. These cases seem to represent an unusual primarily extra-axial presentation of pleomorphic xanthoastrocytoma and may account for at least some of the previously reported cases of primary meningeal glioma and/or glial fibrillary acidic protein-immunoreactive meningioma variants. We suggest that BRAF mutation analysis be considered in all meningeal lesions showing atypical histologic or immunohistochemical profiles, particularly those exhibiting glial differentiation, as a diagnostic aid and possible indication for targeted therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352988      PMCID: PMC4777522          DOI: 10.1097/NEN.0000000000000240

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  47 in total

1.  Pleomorphic xanthoastrocytomas: institutional experience of 18 patients.

Authors:  Taemin Oh; Gurvinder Kaur; Michelle Madden; Orin Bloch; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2014-06-17       Impact factor: 1.961

2.  BRAF V600 point mutation is not present in relapsing meningioma.

Authors:  Fabien Forest; Violaine Yvorel; François Vassal; Béatrice Trombert; Jean-Marc Dumollard; Christophe Nuti; Michel Péoc'h
Journal:  Clin Neuropathol       Date:  2015 May-Jun       Impact factor: 1.368

3.  Primary extracerebral meningeal glioblastoma: clinical and pathological analysis.

Authors:  P Stavrinou; I Magras; L C Stavrinou; T Zaraboukas; K S Polyzoidis; P Selviaridis
Journal:  Cent Eur Neurosurg       Date:  2010-02-19

4.  Primary diffuse leptomeningeal gliomatosis.

Authors:  P Bailey; Y Robitaille
Journal:  Can J Neurol Sci       Date:  1985-08       Impact factor: 2.104

5.  Pleomorphic xanthoastrocytoma with CT and MRI appearance of meningioma.

Authors:  A Pierallini; M Bonamini; D Di Stefano; P Siciliano; L Bozzao
Journal:  Neuroradiology       Date:  1999-01       Impact factor: 2.804

6.  Primary meningeal glioma.

Authors:  K Opeskin; R M Anderson; D H Nye
Journal:  Pathology       Date:  1994-01       Impact factor: 5.306

7.  Extracerebral leptomeningeal astrocytoma mimicking a meningioma.

Authors:  D S Horoupian; F Lax; K Suzuki
Journal:  Arch Pathol Lab Med       Date:  1979-12       Impact factor: 5.534

8.  MR of isolated leptomeningeal glioma.

Authors:  O Krief; L Monnier; P Cornu; J F Foncin; D Dormont; C Marsault
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

Review 9.  A polycystic variant of a primary intracranial leptomeningeal astrocytoma: case report and literature review.

Authors:  Antonio De Tommasi; Giuseppe Occhiogrosso; Claudio De Tommasi; Sabino Luzzi; Antonella Cimmino; Pasqualino Ciappetta
Journal:  World J Surg Oncol       Date:  2007-06-23       Impact factor: 2.754

10.  Exomic sequencing of four rare central nervous system tumor types.

Authors:  Chetan Bettegowda; Nishant Agrawal; Yuchen Jiao; Yuxuan Wang; Laura D Wood; Fausto J Rodriguez; Ralph H Hruban; Gary L Gallia; Zev A Binder; Callen J Riggins; Vafi Salmasi; Gregory J Riggins; Zachary J Reitman; Ahmed Rasheed; Stephen Keir; Sueli Shinjo; Suely Marie; Roger McLendon; George Jallo; Bert Vogelstein; Darell Bigner; Hai Yan; Kenneth W Kinzler; Nickolas Papadopoulos
Journal:  Oncotarget       Date:  2013-04
View more
  16 in total

1.  Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.

Authors:  Norman L Lehman; Eyas M Hattab; Bret C Mobley; Aisulu Usubalieva; Matthew J Schniederjan; Roger E McLendon; Werner Paulus; Elisabeth J Rushing; Maria-Magdalena Georgescu; Marta Couce; Mohanpal S Dulai; Mark L Cohen; Christopher R Pierson; Jack M Raisanen; Sarah E Martin; Trang D Lehman; Eric S Lipp; Jose M Bonnin; Mousa A Al-Abbadi; Kara Kenworthy; Kevin Zhao; Nehad Mohamed; Guojuan Zhang; Weiqiang Zhao
Journal:  Neuro Oncol       Date:  2016-07-14       Impact factor: 12.300

Review 2.  New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Authors:  Michael Karsy; Jian Guan; Adam L Cohen; Randy L Jensen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

3.  Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Authors:  Nicholas F Brown; Thomas Carter; Paul Mulholland
Journal:  CNS Oncol       Date:  2016-10-26

4.  Dabrafenib and trametinib in BRAFV600E mutated glioma.

Authors:  Nicholas F Brown; Thomas Carter; Neil Kitchen; Paul Mulholland
Journal:  CNS Oncol       Date:  2017-10-06

5.  Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.

Authors:  Felix Behling; Alonso Barrantes-Freer; Marco Skardelly; Maike Nieser; Arne Christians; Florian Stockhammer; Veit Rohde; Marcos Tatagiba; Christian Hartmann; Christine Stadelmann; Jens Schittenhelm
Journal:  Diagn Pathol       Date:  2016-06-27       Impact factor: 2.644

6.  Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Authors:  Michael C Burger; Michael W Ronellenfitsch; Nadja I Lorenz; Marlies Wagner; Martin Voss; David Capper; Theophilos Tzaridis; Ulrich Herrlinger; Joachim P Steinbach; Gabriele Stoffels; Karl-Josef Langen; Christian Brandts; Christian Senft; Patrick N Harter; Oliver Bähr
Journal:  Oncol Rep       Date:  2017-10-02       Impact factor: 3.906

7.  BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma.

Authors:  Denis Migliorini; Diego Aguiar; Maria-Isabel Vargas; Alexander Lobrinus; Pierre-Yves Dietrich
Journal:  Neurology       Date:  2017-02-24       Impact factor: 9.910

8.  BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.

Authors:  Rimas V Lukas; Ryan T Merrell
Journal:  CNS Oncol       Date:  2018-04-30

Review 9.  BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Authors:  Karisa C Schreck; Stuart A Grossman; Christine A Pratilas
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

10.  Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma: A Systematic Review and Individual Patient Data Analysis of 325 Cases.

Authors:  Supriya Mallick; Prashanth Giridhar; Rony Benson; Wineeta Melgandi; Goura Kishor Rath
Journal:  J Neurosci Rural Pract       Date:  2019-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.